Over het archief
Het OWA, het open archief van het Waterbouwkundig Laboratorium heeft tot doel alle vrij toegankelijke onderzoeksresultaten van dit instituut in digitale vorm aan te bieden. Op die manier wil het de zichtbaarheid, verspreiding en gebruik van deze onderzoeksresultaten, alsook de wetenschappelijke communicatie maximaal bevorderen.
Dit archief wordt uitgebouwd en beheerd volgens de principes van de Open Access Movement, en het daaruit ontstane Open Archives Initiative.
Basisinformatie over ‘Open Access to scholarly information'.
| From gene to bioactive product: Exploiting marine genomics for an innovative and sustainable European blue biotechnology industry |
| www.bluegenics.eu/
|
|
Acroniem: BLUEGENICS
Periode: Augustus 2012 tot 2016
Status: Afgelopen
|
|
| Instituten (15) |
Top |
- University of Naples, meer, partner
- National Natural History Museum Paris (MNHN), meer, partner
- Uppsala University, meer, partner
- Chinese Academy of Sciences; National Research Center for Geoanalysis, meer
- Institut Ruđer Bošković, meer
- Rheinische Friedrich-Wilhelms-Universität Bonn, meer
- Matís ohf, meer
- Biotrend - Inovação e Engenharia em Biotecnologia, SA, meer
- Galapagos istrazivacki centar doo za istrazivanje I razvoj, meer
- Prokazyme ehf, meer
- Sæbýli ehf, meer
- NanotecMARIN GmbH, meer
- BIOALVO S.A., meer
- ManRos Therapeutics, meer
- University of St Andrews (USTAN), meer, partner
|
| Abstract |
Marine organisms, in particular sponges and their associated microorganisms, are an inexhaustible source of novel bioactive (lead) compounds for biomedical application. Industrial exploitation of this natural resource using traditional approaches is, however, hampered, with a few exceptions, by unsolvable supply problems - despite of numerous efforts in the past. Therefore, there is, very likely, only one way: to start from the genes encoding the bioproducts, or their biosynthetic pathways, to sustainably obtain the active molecules in sufficient amounts. The aim of the presented industry-driven integrating project is to combine the knowledge in marine genomics, chemogenetics and advanced chemistry to produce recombinantly prepared novel secondary metabolite (lead) compounds and analogous from them, as well as harmacologically active peptides, and to bring them up to the pre-clinical, and hopefully also to the clinical studies. This
ambitious approach is based on breakthrough discoveries and the results of previous successful EU projects of members of the applying consortium, including European leaders (or worldwide leaders) in marine (sponge) genomics, metagenomics (polyketide synthase clusters), combinatorial biosynthesis and marine natural product chemistry/ structure elucidation. This multidisciplinary project, driven by high-tech genomics-based SMEs with dedicated interest in bringing marine-biotechnology-derived products to the market, will also involve the discovery and sustainable production of bioactive molecules from hitherto unexploited extreme environments, such as hydrothermal vents and deepsea sources, and the expression/scale-up of unique enzymes/proteins of biomedical and biotechnological interest. The molecular-biology-based strategies developed in this project for a sustainable exploitation of aquatic molecular biodiversity will further strengthen the international position and effectiveness of European (SME-based) blue biotechnology industry. |
IMIS is ontwikkeld en wordt gehost door het VLIZ.
